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Background: Although cognitive deﬁcits have consistently been characterized as core features of
schizophrenia, they have not been incorporated into deﬁnitions of remission. Furthermore, just a few
studies have examined the relationship between cognitive deﬁcits and symptomatic remission. The main aim
of the present study is to evaluate the executive functioning of nonremitted schizophrenia patients.
Methods: 72 remitted and 42 nonremitted schizophrenia patients, and 119 healthy controls were examined.
Subjects were tested with a comprehensive battery of cognitive tests, including a measure to assess the
general components of executive functioning and individual tasks to tap the three speciﬁc executive
dimensions assessed in the present study, namely updating, shifting and inhibition.
Results: Schizophrenia subjects performed poorly on general executive functioning and shifting tasks in
comparison to healthy controls. Remitted subjects performed better than nonremitted on inhibition and
updating tasks. Whereas being a male and showing decreases in updating increase the chances of being in the
nonremitted schizophrenia subjects group, increases in shifting and updating enhance the odds of being in
the healthy control group.
Conclusion:The presentﬁndings suggest that executive function deﬁcits are present in chronic schizophrenic patients.
In addition, speciﬁc executive processes might be associated to symptom remission. Future studies examining
prospectively ﬁrst-episode, drug naive patients diagnosed with schizophrenia may be especially elucidative.© 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Schizophrenia (SCZ) is a chronic, disabling neuropsychiatric disease
that affects 0.3% to 1.6% of the general population (Jablensky, 2000;
Tandon et al., 2008). Notwithstanding the reﬁnement of knowledge
regarding its clinical course and advances in pharmacological and
nonpharmacological interventions, the majority of individuals with
schizophrenia still experience persistent incapacitating symptomatol-
ogy and multiple relapses (Kane and Correll, 2010).
Different studies have found that remission, which is estimated to
be achieved in only one-third of schizophrenia subjects (Lasser et al.,
2007), is a good predictor of functional outcome (Andreasen et al.,
2005; Emsley et al., 2013; Helldin et al., 2007). In order to provide a
greater clarity about treatment goals and an improved framework for
designing trials and test its effectiveness, the Remission in Schizo-
phrenia Working Group (RSWG) has proposed consensual and
operational criteria for remission in schizophrenia. According toea-Souza).
open access article under the CC BRSWG, remission is deﬁned as a state in which individuals with
schizophrenia have experienced an improvement in core signs and
symptoms considering that any remaining symptoms are of such low
intensity that they no longer interfere signiﬁcantlywith behavior and
are below the threshold typically used for establishing diagnose
(Andreasen et al., 2005). The proposed symptom-based criteria
include the seven diagnostically relevant items from the DSM-IV,
which are cross-matched with eight items from the Positive and
Negative Symptoms Scale (PANSS) (Kay et al., 1987). These eight
items must score within a symptom level ≤3 points (mild or better
severity) and include: delusions, unusual thought content, halluci-
natory behavior, conceptual disorganization, mannerisms/posturing,
blunted affect, passive/apathetic social withdrawal, lack of sponta-
neity and ﬂow of conversation. There is also a minimum period of six
months in which the symptoms severity must be maintained
(Andreasen et al., 2005; Lambert et al., 2010).
Although clinical subtypes have been used in psychiatric
nosology as a conceptual framework for understanding schizophre-
nia in past century, they have not proved useful for prognostic
purposes (Braff et al., 2013). More recently, studies investigating
different biomarkers have also reported disappointing ﬁndingsY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tently been considered as core features of schizophrenia (Green and
Harvey, 2014). They are present prior to onset of psychosis, are
correlated withmeasurable brain dysfunctionmore than any clinical
manifestation of the illness, are signiﬁcantly associated with
functioning in areas such as work performance, social relationships
and independent living, and are increasingly considered as an
important target for treatment (Green et al., 2000; Keef, 2008; Lewis,
2004; Palmer et al., 2009). Given the importance of reentering
individuals with schizophrenia to community the Measurement and
Treatment Research to Improve Cognition in Schizophrenia (MATRICS)
initiative of the U.S. National Institute of Mental Health (NIMH) set the
development of a consensus cognitive battery (MCCB) for measuring
cognition in schizophrenia, aiming to guide the design of clinical trials
for cognition enhancing agents and encouraging new researches
(Green and Nuechterlein, 2004).
It is noteworthy that cognitive impairments have not been
incorporated into instrumental concepts of remission in schizophre-
nia, despite their clinical relevance (Andreasen et al., 2005; Helldin et
al., 2006). Many studies have shown that schizophrenia subjects
exhibit executive deﬁcits, which are related to treatment refractori-
ness and poor functional outcomes and are likely to contribute to
other cognitive deﬁcits (Kerns et al., 2008). In addition, frontal lobe
functioning measures have also been associated with recovery
(Kopelowics et al., 2005). Executive functioning is a multidimensional
process that covers a wide range of skills, which are used to guide
behavior toward goals and to adapt to novel situations. It is
considered the most sophisticated dimension of human behavior
necessary for appropriate, socially responsible, independent and
productive adult conduct. Executive processes are mediated by
prefrontal regions and are associated with the ability to perform
high-level tasks involving planning, organizing, initiating, monitoring
and adapting behavior (Banish, 2009; Jurado and Rosselli, 2007; Lezak
et al., 2004; Wilson et al., 2003).
The heterogeneity of the dysexecutive syndrome in schizophrenia,
based on the theoretical model of Miyake et al. (2000), which
postulates the notion, originally proposed by Teuber (1972), that
different aspects of executive functioning correlate with one another,
thus tapping some common underlying ability (unity), but also show
some separability (diversity), has been emphasized in studies with
chronic schizophrenia patients (Raffard and Bayard, 2012). Previous
ﬁndings have suggested a speciﬁc impairment in the ability to update
working memory in schizophrenia, and that this is associated with
poor engagement with the environment (Galletly et al., 2006). Few
studies have examined the relationship between cognitive deﬁcits
and symptomatic remission, and there were no clear evidence
whether increased cognitive abilities, more speciﬁcally executive
function, are a contributing factor for achieving remission. Some of
these studies have found no signiﬁcant differences in executive
processes of fully remitted patients and healthy controls (Braw et al.,
2012) or of remitted versus nonremitted schizophrenic patients
(Brissos et al., 2011). On the other hand, some studies revealed
marked differences in executive functioning between patients who
have met the remission criteria and those who haven’t (Helldin et al.,
2006; Hofer et al., 2011). At least part of this apparent inconsistency
might be explained by methodological issues. Executive function tests
differ in their complexity, speciﬁcity of the required speciﬁc executive
abilities and even non-executive processes (Wood et al., 2009).
None of the previous studies systematically administered multiple
executive tasks to understand the heterogeneity of the executive
function impairments during symptomatic remission in schizophre-
nia patients. Therefore, the nature of how speciﬁc aspects of
symptomatic remission affect, and are affected by, speciﬁc aspects
of executive processes remains unclear.The main aim of present study is to examine speciﬁc aspects of
executive function of both remitted and nonremitted subjects,
comparing with healthy controls. We hypothesized that both
remitted and nonremitted subjects have executive function deﬁcits
in comparison tomatched control group and that severity of deﬁcits is
greater in nonremitted subjectsMaterials and methods
Subjects
A total of 114 subjects with DSM-IV schizophrenia were enrolled.
Seventy-two (44 males; age = 35.98 ± 9.02 years and 28 females; age =
40.11 ± 11.57 years) patients were classiﬁed as remitted and 42
(36 males; age =35.86 ± 9.39 years and 6 females; age =
32.33 ± 9.48 years) as nonremitted. 119 healthy controls (70 males;
age = 33.56 ± 9.85 years and 49 females; age = 34.71 ± 11.28 years)
were included in a cross-sectional study. Subjectswhowere not able to read
and/or understand instructions of cognitive tests were excluded. Patients
were recruited fromanoutpatientunit for treatmentof schizophrenia, The
Schizophrenia Program, Federal University of Sao Paulo (PROESQ). All
participants provided written informed consent and the local ethics
committee approved the study.
Diagnosis was assessed by using The Structured Clinical Interview
for DSM-IV (SCID-I). Symptom severity was assessed by means of the
Positive and Negative Symptoms Scale (PANSS) (Kay et al., 1987).
Trained psychiatrists conducted all interviews.
To assess remission, the criteria proposed by Andreasen et al.
(2005) were used, according to which 8 items of PANSS (delusions,
conceptual disorganization, unusual thought content, hallucinatory
behavior, mannerisms/posturing, blunted affect, social withdrawal
and lack of spontaneity) should be scored ≤ 3 (mild). Yet, symptom-
atic remission criteria should be present for at least 6 months. Finally,
the mean score on each group by gender was 69.72 ± 11.60 and
78.67 ± 2.25 for male and female individuals of nonremitted schizo-
phrenia group and 49.8 ± 10.68 and 50.07 ± 11.18 for male and female
individuals of remitted schizophrenia group, respectively.Instruments
Nonverbal Intelligence Task (R-1)
This scale was created to allow measures of intelligence in low
literacy populations. This test highly correlates with the Raven's
Colored Progressive Matrices Test (r = 0.76, p = 0.001), and was
chosen for the high frequency of low literacy found in the Brazilian
schizophrenia population (Oliveira, 2002).Computerized Stroop Test
The computerized Stroop Test (Capovilla et al., 2009) was used as a
measure of inhibition. This test was composed of three parts of 24
stimuli each. In the ﬁrst part, the subject was asked to read the word
that appears in the computer display and the stimuli are names of four
colors (yellow, blue, green and red) written in capital black font. The
objective of this part was to evaluate the automation of reading, which
was essential for the expected effect. The second part comprises 24
colored circles, six drawn in each of the four colors. Each circle was
displayed for 40 ms and the participant had to name the color of the
circle as fast as he/she can. The objective of this part was to provide a
baseline measure for reaction time. In the third part of the test the
subject had to read the color name but the stimuli were divergent; the
41T. Rabanea-Souza et al. / Schizophrenia Research: Cognition 3 (2016) 39–46word was displayed in a color different from the color it actually
names. Each word was displayed for 40 ms and the participant had to
name the color in which the word was written as fast as he/she can. In
all the three parts, the reaction time and the number of correct
answers were recorded using a microphone.
The performance in the Stroop Test depends on the interference
of automatic processing of reading in the color identiﬁcation. The
scores both for reaction time and for the number of correct answers
were based on the subtraction between the mean results in parts
three and two.
Keep Track Task
The Keep Track Task was used to measure updating (Berberian
et al., 2015). In this task, adapted from Yntema (1963), ﬁrst several
target categories were shown in the computer screen (animals, colors,
countries, distances, metals, and relatives). Then, ﬁfteen words were
verbally presented in random order for 1500 ms apiece with the
target categories remaining at the bottom of the computer screen.
Each list had 2 to 3 exemplars from one of six possible categories. The
task was to remember the last word presented in each of the target
categories at the end of the trial. Thus, participants had to monitor the
words presented and update their working memory representations
for the appropriate categories when the presented word was a
member of one of the target categories. The ﬁrst three trials had four
categories to be fulﬁlled, and the last three had ﬁve. The dependent
measure was the proportion of words recalled correctly.
Letter Memory Task
Letter Memory Task was the second updating measure (Berberian
et al., 2015). In this task, adapted from Morris and Jones (1990),
several letters from a list were sequentially presented for 2000 ms per
letter. The task was to recall the last two letters of each list. The
instructions required the participants to rehearse out loud the last 2
letters bymentally adding themost recent letter and dropping the 3rd
letter back and then saying the new string of 2 letters out loud. This
instruction was given to ensure that participants were performing
continuous updating. Although previous studies have used sequences
ranging from 4 to 9 words, we had to adapt the task for a smaller
sequence because most of the patients could not start performance
with larger sequences.
Number–Letter Task
The Number–letter Task adapted from Rogers and Monsell (1995)
was used to assess shifting. In this task a number–letter pair (e.g., 7G)
was presented in one of four quadrants on the computer screen. In the
ﬁrst phase participants had to indicate whether the number was odd
or even when the pair was presented in either of the top two
quadrants. In the second phase, they had to indicate whether the
letter was a consonant or a vowel when the pair was presented in the
bottom two quadrants. Finally, in the last phase stimuli were
presented in all the four quadrants, in a clockwise rotation and
participants had to shift between these two types of categorization
operations. The outcome variablewas themean of the total time taken
to complete two ﬁrst phases minus the total time taken to complete
the last phase.
Plus–Minus Task
The Plus–Minus Task adapted from Jersild (1927) was used as a
second measure of shifting. In this task, three lists of 30 two-digit
numbers were presented in the top of the computer screen. On the
ﬁrst list, the participants were instructed to add 3 to each number and
speak out loud their answers. On the second list, they had to subtract 3
from each number. Finally, on the third list, the participants were
required to alternate between adding 3 to and subtracting 3 from thenumbers (i.e., add 3 to the ﬁrst number, subtract 3 from the second
number, and so on). All the answers were recorded by using a
microphone. The outcome variable was the mean of the total time
taken to complete two ﬁrst phases minus the total time taken to
complete the third phase.Tower of London Test
The Tower of London Test (TOL) was developed to identify
impairments of supervening planning processes that monitor lower
level structures, which are associated with frontal lobe dysfunction
and are often incorporated in the executive function concept as a
central cognitive component of many problem-solving activities
(Krikorian et al., 1994). Although multiple strategies involving
different sub-processes can be used in solving the TOL puzzle, the
Tower of London is a neuropsychological instrument of choice to
measure planning ability, the process of forming an effective task plan
by activation of multiple goals or action constraints which sets the
very general element (unity) of executive function (Duncan et al.,
1997). The Tower of London, along with the similar Tower of Hanoi,
was chosen mainly because it is frequently used as a measure of the
integrity and complexity of executive function (Miyake et al., 2000).
The Tower of London was used as a measure of general executive
functioning. In Tower of London, participants were ﬁrst shown three
colored discs that are arranged in three pegs. The colored discs must
be moved one-by-one from an initial state to matched goal states
determined by the examiner. Subjects were instructed to use as few
movements as possible to reach the goal and to nevermovemore than
one disc simultaneously or to place a disc out of the peg. The complete
test comprises 12 items, with a rising complexity level. The dependent
measure for this task was the total number of moves taken to
complete the target problems.Statistical analysis
All statistical analyses were performed with the SPSS for Windows
software, version 21.0 (SPSS, Chicago, Illinois). Alpha was set at
p b .05. Comparisons involving categorical variables such as gender
and handedness were performed with a Chi-square test and
comparisons involving age were assessed with Kruskal–Wallis
non-parametric test, since age had a non-normal distribution as
assessed by Shapiro–Wilk’s test.
Based on ﬁndings from previous studies (Miyake et al., 2000),
tests were classiﬁed according to their corresponding construct:
mental set shifting (“Shifting”, Plus–Minus and Number–Letter tests);
information update and monitoring (“Updating”; Keep Track and
Letter Memory tests); and inhibition of prepotent responses (“Inhi-
bition”; Computerized Stroop). The equally weighted composite score
of each construct was calculated. Comparisons involving those
variables were assessed with Kruskal–Wallis non-parametric test,
since they also had a non-normal distribution as assessed by Shapiro–
Wilk’s test.
A multinomial logistic regression was performed to examine
effects of gender, education level, intelligence, general executive
measures, mental set shifting, information update and monitoring,
and inhibition of prepotent responses on the likelihood that
participants would belong to remitted, nonremitted or control
group. In order to understand further ‘proﬁles’, a cross validated
Exhaustive CHAID classiﬁcation tree model was run using the same
variables. Finally, a multiple regression was run to predict intelligence
(R1percentile) and general executive functioning (performance on Tower
of London) from shifting, updating, inhibition and group assignment
(remitted, nonremitted and control).
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Groups were matched for age (Kruskal–Wallis; H(2) = 5.836;
p = 0.54) and handedness (χ2(2) = 0.75; p = 0.963), but not for
gender (χ2(2) = 10.274; p = 0.006), education level (χ2(8) =
89.250; p b 0.001), intelligence, general executive functioning, shift-
ing, inhibition and updating. Please refer to Table 1 for group
comparison results.
Between-group differences were found in all neuropsychological
tasks, in which healthy control group had the highest performance
means followed by the remitted group and the nonremitted group,
which presented the lowest mean. Regarding pairwise comparisons,
we observed differences between nonremitted and controls for
intelligence; between both patients groups and controls for general
executive functioning and shifting; and, ﬁnally, between nonremitted
and the other two groups for inhibition and updating.
Gender differences on age, PANSS total score and duration of
disease were assessed with Mann–Whitney nonparametric test. Only
comparisons involving PANSS scores were signiﬁcant (nonremitted
group; males = 69.72 ± 11.607 vs. females = 78.67 ± 2.251; U =
359.500; p = 0.005).
The multinomial logistic regression model (χ2(16) = 325.528,
p b 0.001) explained 86.7% (Nagelkerke R2) of the variance in
remitted subjects and correctly classiﬁed 86.7% of cases. Three out
of seven predictor variables were statistically signiﬁcant: information
update and monitoring, mental set shifting and gender (as shown in
Table 2). Using the remitted group as a reference, we observed that
decreasing performance on updating would slightly increase the odds
of the individual to belong to the nonremitted group. In addition, male
individuals had 7.14 more chance to belong to the nonremitted group
than to the remitted group. Regarding the comparisons involving all
groups, we observed that one unit increase in shifting and updating
performance would increase by 164% and 16%, respectively, the chances
of the individual to belong to healthy control group.
With the objective of further understanding the classiﬁcation
proﬁles of the individuals, a cross-validated Exhaustive CHAID
classiﬁcation tree model was run using the same variables described
on the above table (Fig. 1).
The ﬁrst division shows that all schizophrenia subjects had scores
below or equal to 2.142 on shifting, in contrast with individuals in
healthy control group (χ2(2) = 225.134, p b 0.001). At the second
division, an association between gender and symptom remission
(χ2(2) = 8.001, p = 0.018) was observed, where 85.7% of the
individuals on nonremitted group and 61.1% of the individuals on
the remitted group were male. On the last level, an association
between performance in updating and symptom remission (χ2(6) =Table 1
Mean and standard deviation of performance on R1 (IQ), Tower of London (general execut
NR-SCZ mean R-SCZ mean Controls mean Three gr
R1 22.60 ± 15.992 33.00 ± 27.591 38.91 ± 23.181 H(2) =
p b .001
TOL 27.90 ± 3.512 29.31 ± 4.127 30.92 ± 2.970 H(2) =
p b .001
“Shifting” 1.366 ± .198 1.339 ± .199 16.333 ± 11.723 H(2) =
p b .001
“Inhibition” .752 ± .432 .614 ± .390 .427 ± .182 H(2) =
p b .001
“Updating” 58.059 ± 12.603 67.069 ± 13.476 73.882 ± 10.126 H(2) =
p b .001
Nonremitted schizophrenia patients (NR-SCZ), remitted schizophrenia patients (R-SCZ) and
comparing the differences between groups for these variables.
⁎ Statistically signiﬁcant (p b .05).22.825, p = 0.039) was observed, where 83.3% of the individuals who
scored higher than 72 on updating belonged to the remitted group.
The ranges for R1 percentile were 1 to 60 in nonremitted, 1 to 95 in
remitted, and 5 to 95 in control group. A multiple regression was run to
predict intelligence (R1percentile) and general executive functioning
(performance on Tower of London) from shifting, updating, inhibition
and group (remitted, nonremitted and healthy control groups). The
assumptions of linearity, independence of errors, homoscedasticity,
unusual points and normality of residuals were met. Those variables
predicted intelligence and executive functioning (respectively,
F(4,228) = 19.513, p b 0.001, adj R2 = 0.242; F(4,228) = 13.500,
p b 0.001, adj R2 = 0.177).
Group also showed prediction of R1 score, although it did not reach
the established level of signiﬁcance (p b 0.05). The results are
summarized in Table 3.
Finally, analyses examining the relationship between sociodemo-
graphic and clinical variables with symptom remission showed an
association between symptom remission and years of education,
gender (female), occupation and schizophrenia clinical subtype.
Results are presented in the Table 4.
Associations involving symptom remission and gender, schizophre-
nia subtype, occupationandyearsof education,weremoderate (Cramer’s
V = 0.254, p = 0.006 for gender; Cramer’s V = 0.415, p b 0.001 for
schizophrenia subtype; Cramer’s V = 0.201, p = 0.028 for occupation
and Cramer’s V = 0.313, p = 0.025 for years of education).
Discussion
The present study examined executive functioning in remitted and
nonremitted schizophrenia subjects. In line with a priori hypothesis,
schizophrenia subjects performed poorly on the general executive
task (TOL) when compared to healthy controls. Remitted and
nonremitted schizophrenia patients performed poorly on the tasks
that tap the three speciﬁc executive dimensions likely implicated in
the performance of general executive task: shifting, inhibition and
updating. In addition, comparisons involving patient subgroups
suggested that nonremitted subjects have impairments on tasks
tapping updating and inhibition as compared with patients who
attained remission.
Different studies have shown that intelligence measures are
largely related to prognosis in schizophrenia. A robust body of
evidence suggests that higher intelligence levels are associated with
an increased likelihood of remission (Aylwand et al., 1984).
Furthermore, longitudinal observational studies have suggested that
the lower the performance on standardized measures of intelligence
in childhood, adolescence and young adulthood, the higher is the riskive functioning), shifting, inhibition and updating for each group.
oups NR-SCZ and R-SCZ NR-SCZ and Controls R-SCZ and Controls
15.448
⁎
U(112) = −23.455
p = .214
U(159) = −45.480
p b .001⁎
U(189) = −22.025
p = .083
22.538
⁎
U(112) = −31.029
p = .052
U(159) = −55.700
p b .001⁎
U(189) = −24.671
p = .041⁎
162.699
⁎
U(112) = 6.805
p N .999
U(159) = −115.091
p b .001⁎
U(189) = −108.286
p b .001⁎
31.467
⁎
U(112) = 34.990
p = .002⁎
U(159) = 63.743
p b .001⁎
U(189) = 28.753
p = .084
45.142
⁎
U(112) = −44.235
p = .002⁎
U(159) = −79.223
p b .001⁎
U(189) = −34.998
p = .002⁎
healthy controls (controls). Results of Kruskal–Wallis and post hoc Mann–Whitney tests
Table 2
Summary of multinomial logistic regression analysis.
Groupa Variable B S.E. Wald df Sig. Odds 95% C.I. for Odds Ratio
Ratio Lower Upper
Nonremitted SCZ subjects Intercept − .358 1.776 .041 1 .840
"Updating" − .054 .019 8.056 1 .005⁎ .947 .912 .983
"Shifting" − .047 .305 .024 1 .877 .954 .525 1.733
"Inhibition" .711 .598 1.411 1 .235 2.036 .630 6.576
Male 1.966 .609 10.411 1 .001⁎ 7.145 2.164 23.593
Femaleb 0 0
Finished Middle school or less 2.052 1.186 2.996 1 .083 7.784 .762 79.506
High school incomplete 1.899 1.228 2.391 1 .122 6.680 .602 74.157
Finished High School .914 1.166 .615 1 .433 2.495 .254 24.517
Undergraduate 1.165 1.228 .899 1 .343 3.205 .289 35.604
Graduateb 0 0
Healthy controls Intercept −15.890 6.085 6.820 1 .009
"Updating" .150 .068 4.915 1 .027⁎ 1.162 1.018 1.328
"Shifting" .973 .268 13.222 1 b .001⁎ 2.646 1.566 4.471
"Inhibition" −3.947 2.575 2.349 1 .125 .019 .000 3.005
Male −1.022 1.218 .704 1 .401 .360 .033 3.916
Femaleb 0 0
Finished Middle school or less 6.068 3.415 3.157 1 .076 431.719 .535 348543.502
High school incomplete 2.305 3.502 .433 1 .510 10.020 .010 9584.593
Finished High School 2.584 3.205 .650 1 .420 13.244 .025 7087.350
Undergraduate −15.571 .000 1 1.729x10−7 1.729 x10−7 1.729 x10−7
Graduateb 0 0
Remitted SCZ subjects were used as reference for comparison with the other groups.
a The reference category of the dependent variable for pairwise comparison is Remitted Schizophrenic Patients.
b These are the reference categories for pairwise comparison of gender and years of education factors.
⁎ p-value below .050
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lower intelligence levels at ﬁrst episode of psychosis predicted a
schizophrenia diagnosis (Díaz-Caneja et al., 2015) and more severe
symptoms (Leeson et al., 2011). Despite the observed association
between intelligence and outcome in schizophrenia, general intellec-
tual ability appears to remain stable after an initial decline associated
with illness onset and concomitant, progressive loss of cortical matter
(Rapoport et al., 2005; Goshman et al., 2005). In the present study,
nonremitted, but not remitted schizophrenia patients, performed
poorly on non-verbal intelligence tasks as compared to healthy
controls, suggesting that higher level of intelligence is associated to
remission.
Cognitive domains such as executive functioning are characteris-
tically impaired in schizophrenia subjects irrespective of overall
cognitive functioning, strengthening the argument that neurocogni-
tive deﬁcits are core deﬁcits of illness (Weickert et al., 2000). Present
ﬁndings indicate that, even remitted schizophrenia patients whose
intelligence did not differ signiﬁcantly from healthy controls
performed poorly on general executive tasks. Nevertheless, no
difference between remitted and nonremitted patients was found
regarding those tasks. This ﬁnding suggests that the neuropsycholog-
ical instrument to assess the general cognitive component of
executive functioning process (TOL) used might be useful to
differentiate healthy controls from chronic schizophrenia patients,
but might not contribute to better understanding the nature of the
executive function impairments in symptomatic remission.
Applying the framework of Miyake et al. (2000), the individual
tasks (manifest variables) were chosen to tap the three speciﬁc
executive dimensions (latent variables) examined in the present
study, namely updating, shifting and inhibition. In general, increasing
performance in all speciﬁc executive processes was associatedwith an
increased chance of belonging to the healthy control group. The
results showed that one unit increase in shifting and updating
performance would increase by 164% and by 16%, respectively, the
chances of belonging to the control group, suggesting that a poorperformance on shifting and updating might be a good predictor of
schizophrenia diagnosis. We also observed that increasing perfor-
mance on updating and inhibition slightly affects the odds of
belonging to remitted schizophrenia patients group, suggesting that
a better performance on updating and inhibition might increase the
likelihood of exhibiting symptom remission.
As mentioned earlier, only about a third of all patients reach
remission (Lasser et al., 2007). The remission rates found in present
study were signiﬁcantly higher: of 80 males, 44 were in remission
(55%) and of 34 females, 28 were in remission (82.4%). This ﬁnding
might be explained at least in part by the fact that subjects were
recruited from a university outpatient unit where subjects were seen
in an interdisciplinary, intensive care program, which ensures
medication adherence during treatment and clinical effectiveness,
which improves treatment adherence (Tandon et al., 2006). All
variables (outpatient population, treatment adherence and interdis-
ciplinary, intensive care) have been associated to higher remission
rates (Gasquet et al., 2008; Lambert et al., 2010; Malla et al., 2002). In
line with the present ﬁndings, different studies have suggested that
females, as compared to males, with schizophrenia show greater rates
of symptomatic remission (Carpiniello et al., 2012; Lambert et al.,
2010). However, a difference between male and female gender was
found for PANSS total score in nonremitted group, suggesting a more
severe expression of the illness in females. This ﬁnding contrasts with
previous studies in which male gender was associated with more
severe manifestations of the disease (Castle and Murray, 1991).
Analyses examining the effect of sociodemographic variables
showed associations involving symptom remission and years of
education and occupational adjustment. Those ﬁndings are in line
with results of previous studies that have found an association
between higher educational level (Geddes et al., 1994), better
occupational adjustment (Spiker et al., 1987) and remission
(McGlashan, 1988).
The present study has different strengths. First, sample size is
considerably large as compared to most studies examining the
Fig. 1. Classiﬁcation tree.
44 T. Rabanea-Souza et al. / Schizophrenia Research: Cognition 3 (2016) 39–46relationship between cognitive functioning and remission in schizo-
phrenia patients. Second, a validatedmodel of executive functionwith
multiple tasks providing purer measures of executive processes was
applied. To our knowledge, this is the ﬁrst study that systematically
administered multiple executive tasks based on the theoretical model
of Miyake et al. (2000) to understand the heterogeneity of executiveTable 3
Summary of multiple regression analysis.
Model Unstandardized Coefﬁcients Standardized Coefﬁci
B Std. Error Beta
Predicting TOL Score
Intercept 23.173 1.423 −0.23
"Shiﬁting" − .008 .025 − .023
"Updating" .087 .020 .312
"Inhibition" − .575 .712 − .053
“Group” .824 .424 .173
Predicting R1
Percentile
Intercept −28.545 9.101
"Shiﬁting" − .204 .161 − .094
"Updating" 0.867 0.126 0.467
"Inhibition" 1.258 4.553 .017
“Group” 3.075 2.714 .097
⁎ p-value below .050.function impairments in both remitted and nonremitted patients,
compared to healthy controls. Finally, the present ﬁndings have
demonstrated how speciﬁc aspects of executive function affect, or are
affected by, symptomatic remission in schizophrenia patients.
Nevertheless, the present ﬁndings should be interpreted with
caution, since different limitations were present. Firstly, groups wereents t Sig. 95.0% Conﬁdence Interval for B
Lower Bound Upper Bound
16.284 b .001⁎ 20.369 25.977
− .301 .764 − .057 − .042
4.400 b .001⁎ .48 .126
− .808 .420 −1.978 .827
1.942 .053 .824 .424
−3.136 .002 −46.477 −10.612
−1.268 .206 − .521 .113
6.867 b .001⁎ .618 1.116
.276 .783 −7.713 10.228
1.133 .258 −2.274 8.424
Table 4
Relationship between sociodemographic and clinical variables with symptom
remission.
Pearson
Chi-squared
Asymp. Sig.
(2-sided)
Current antipsychotic in use χ2(12) = 7.818 p = .799
Years of education χ2(4) = 11.168 p = .025⁎
Ethnical group χ2(4) = 2.147 p = .709
Family history of psychiatric diseases χ2(4) = 4.489 p = .344
Gender χ2(1) = 7.6720 p = .006⁎
Marital status χ2(2) = 3.787 p = .152
Occupation χ2(1) = 4.827 p = .028⁎
Religion χ2(24) = 31.660 p = .136
Schizophrenia subtype χ2(2) = 18.726 p b .001⁎
Socioeconomic status χ2(6) = 8.922 p = .178
With whom the patient lives χ2(3) = 3.924 p = .349
⁎ p-value below .050.
45T. Rabanea-Souza et al. / Schizophrenia Research: Cognition 3 (2016) 39–46not matched for gender. Secondly, the present study design does not
allow concluding about causal association involving cognitive func-
tioning and symptomatic remission. Thirdly, the extent to which these
speciﬁc aspects of executive functioning can be divided and treated as
separate variables in a reliable manner should be considered. Finally,
patients examined were chronic and inﬂuence of variables associated
to disease course (e.g., treatment and social functioning) cannot be
ruled out. However, the present ﬁndings are generally consistent with
those reported by studies examining ﬁrst episode subjects (Rund et
al., 2007; Torgalsboen et al., 2014).
In conclusion, the present ﬁndings suggest that executive function
deﬁcits are present in chronic schizophrenic patients. In addition, speciﬁc
executive processes might be associated to symptomatic remission,
suggesting an important role of cognitive remediation in early interven-
tions. Future studies examining prospectively ﬁrst-episode, drug naive
patients diagnosed with schizophrenia may be especially elucidative.
Role of funding source
The present study had ﬁnancial support from Fundação de Amparo
a Pesquisa do Estado de São Paulo (FAPESP, grant numbers 2011/
50740-5 and 2007/58630-9, Brazil).
Contributors
There are no other contributors other than the authors.
Conﬂict of interest
All authors declare that they have no conﬂicts of interest.
Acknowledgements
We acknowledge the contribution of the subjects who took part in
this study, and we thank the Schizophrenia Program (PROESQ) for
recruitment and clinical management of participants.
References
Andreasen, N.C., Carpenter Jr., W.T., Kane, J.M., Lasser, R.A., Mader, S.R., Weinberger,
D.R., 2005. Remission in schizophrenia: proposed criteria and rationale for
consensus. Am. J. Psychiatr. 162, 441–449.
Asor, E., Ben-Shachar, D., 2012. Platets: a possible glance into brain biological processes
in schizophrenia. World J. Psychiatry 2 (6), 124–133.
Aylwand, E., Walker, E., Bettes, B., 1984. Intelligence in schizophrenia: meta-analysis of
the research. Schizophr. Bull. 10 (3), 430–459.Banish, M.T., 2009. Executive function: the search for an integrated account. Curr. Dir.
Psychol. Sci. 18, 89–94.
Berberian, A.A., Gadelha, A., Dias, N.M., Mecca, T.P., Bressan, R.A., Lacerda, A.T., 2015.
Investigation of cognition in schizophrenia: psychometric properties of instru-
ments for assessing working memory updating. J. Bras. Psiquiatr. 64 (3), 238–246.
Braff, D.L., Ryan, J., Rissling, A.J., Carpenter, W.T., 2013. Lack of use in the literature from
the last 20 years supports dropping traditional schizophrenia subtypes from DSM-
5 and ICD-11. Schizophr. Bull. 39 (4), 751–753.
Braw, Y., Benozio, A., Levkovitz, Y., 2012. Executive functioning during full and partial
remission (positive and negative symptomatic remission) of schizophrenia.
Schizophr. Res. 142, 122–128.
Brissos, S., Dias, V.V., Balanzá-Martinez, V., Carita, A.I., Figueira, M.L., 2011. Symptomatic
remission in schizophrenia patients: relationship with social functioning, quality of
life, and neurocognitive performance. Schizophr. Res. 129, 133–136.
Capovilla, A.G., Montiel, J.M., Macedo, E.C., Charin, S., 2009. Teste de stroop
computadorizado Prelo .
Carpiniello, B., Pinna, F., Tusconi, M., Zaccheddu, E., Fatteri, F., 2012. Gender differences
in remission and recovery of schizophrenic and schizoaffective patients: prelim-
inary results of a prospective cohort study. Schizophr. Res. Treat. http://dx.doi.org/
10.1155/2012/576369.
Castle, D.J., Murray, R.M., 1991. The neurodevelopmental basis of sex differences in
schizophrenia. Psychol. Med. 21, 565–575.
Díaz-Caneja, C.M., Pina-Camacho, L., Rodríguez-Quiroga, A., Fraguas, D., Parellada, M.,
Arango, C., 2015. Predictors of outcome in early-onset psychosis: a systematic
review. NPJ Schizophr. http://dx.doi.org/10.1038/npjschz.2014.5.
Duncan, J., Johnson, R., Swales, M., Freer, C., 1997. Frontal lobe deﬁcits after head injury:
unity and diversity of functions. Cogn. Neuropsychol. 14 (5), 713–741.
Emsley, R., Chiliza, B., Asmal, L., Harvey, B.H., 2013. The nature of relapse in schizophrenia.
BMC Psychiatry 13, 50. http://dx.doi.org/10.1186/1471-244X-13-50.
Galletly, C.A., McFariane, A.C., Clark, C.R., 2006. Impaired updating working memory in
schizophrenia. Int. J. Psychophysiol. 63 (3), 265–274.
Gasquet, I., Haro, J.M., Tcherny-Lessenot, S., Chartier, F., Lépine, J.P., 2008. Remission in the
outpatient care of schizophrenia: 3-year results from the Schizophrenia Outpatients
Health Outcomes (SOHO) study in France. Eur. Psychiatry 23 (7), 491–496.
Geddes, J., Mercer, G., Frith, C.D., MacMillan, F., Owens, D.G., Johnstone, E.C., 1994.
Prediction of outcome following a ﬁrst episode of schizophrenia. A follow-up study
of Northwick Park ﬁrst episode subjects. Br. J. Psychiatry 165 (5), 664–668.
Goshman, P.A., Greenstein, D., Sporn, A., Gogtay, N., Keller, B., Shaw, P., Rapoport, J.L.,
2005. IQ stabilization in childhood-onset schizophrenia. Schizophr. Res. 77 (2-3),
271–277.
Green, M.F., Harvey, P.D., 2014. Cognition in schizophrenia: past, present and future.
Schizophr. Res. Cogn. 1, e1–e9.
Green, M.F., Nuechterlein, K.H., 2004. The MATRICS initiative: developing a consensus
cognitive battery for clinical trials. Schizophr. Res. 72 (1), 1–3.
Green, M.F., Kern, R.S., Braff, D.L., Mint, J., 2000. Neurocognitive deﬁcits and functional
outcome in schizophrenia: are we measuring the "right stuff"? Schizophr. Bull. 26 (1),
119–136.
Helldin, L., Kane, J.M., Karilampi, U., Norlander, T., Archer, T., 2006. Remission and
cognitive ability in a cohort of patients with schizophrenia. J. Psychiatr. Res. 40 (8),
738–745.
Helldin, L., Kane, J.M., Karilampi, U., Norlander, T., Archer, T., 2007. Remission in
prognosis of functional outcome: a new dimension in the treatment of patients
with psychotic disorders. Schizophr. Res. 93 (1-3), 160–168.
Hofer, A., Bodner, T., Kaufmann, A., Kemmler, G., Mattarei, U., Pfaffenberger, N.M.,
Rettembacher, M.A., Trebo, E., Yalcin, N., Fleischhacker, W.W., 2011. Symptomatic
remission and neurocognitive deﬁcits in patients with schizophrenia. Psychol. Med.
41 (10), 2131–2139.
Jablensky, A., 2000. Epidemiology of schizophrenia: the global burden of disease and
disability. Eur. Arch. Psychiatry Clin. Neurosci. 250 (6), 274–285.
Jersild, A.T., 1927. Mental set and shift. Arch. Psychol. 89, 5–82.
Jurado, M.B., Rosselli, M., 2007. The elusive nature of executive functions: a review of
our current understanding. Neuropsychol. Rev. 17, 213–233.
Kane, J.M., Correll, C.U., 2010. Past and present progress in the pharmacologic treatment
of schizophrenia. J. Clin. Psychiatry 71 (9), 1115–1124.
Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale for
schizophrenia. Schizophr. Bull. 13, 261–276.
Keef, R.S.E., 2008. Should cognitive impairment be included in the diagnostic criteria for
schizophrenia? World Psychiatry 7 (1), 22–28.
Kerns, J.G., Nuechterlein, K.H., Braver, T.S., Barch, D.M., 2008. Executive functioning
component mechanisms and schizophrenia. Biol. Psychiatry 64, 26–33.
Kopelowics, A., Liberman, R.P., Ventura, J., Zarate, R., Mintz, J., 2005. Neurocognitive
correlates of recovery from schizophrenia. Psychol. Med. 35 (8), 1165–1173.
Krikorian, R., Bartok, J., Gay, N., 1994. Tower of London procedure: a standard method
and developmental data. J. Clin. Exp. Neuropsychol. 16 (6), 840–850.
Lambert, M., Karow, A., Leucht, S., Schimmelmann, B.G., Naber, D., 2010. Remission in
schizophrenia: validity, frequency, predictors, and patients perspective 5 years
later. Dialogues Clin. Neurosci. 13 (3), 393–407.
Lasser, R.A., Nasrallah, H., Helldin, L., Peuskens, J., Kane, J., Docherty, J., Tronco, A.T.,
2007. Remission in schizophrenia: applying recent consensus criteria to reﬁne the
concept. Schizophr. Res. 96 (1-3), 223–231.
Leeson, V.C., Sharma, P., Harrison, M., Ron, M.A., Barnes, T.R.E., Joyce, E.M., 2011. IQ
trajetory, cognitive reserve, and clinical outcome following a ﬁrst episode of
psychosis: a 3-year longitudinal study. Schizophr. Bull. 37 (4), 768–777.
46 T. Rabanea-Souza et al. / Schizophrenia Research: Cognition 3 (2016) 39–46Lewis, R., 2004. Should Cognitive deﬁcit be a diagnostic criterion for schizophrenia?
J. Psychiatry Neurosci. 29 (2), 102–113.
Lezak, M.D., Howieson, D.B., Loring, D.W., 2004. Neuropsychological Assessment.
Oxford University Press, New York.
Maki, P., Veijola, J., Jones, P.B., Murray, G.K., Koponen, H., Tienari, P., Miettunen, J.,
Transkanen, P., Wahlberg, K.E., Koskinen, J., Lauronen, E., Isohanni, M., 2005.
Predictors of schizophrenia — a review. Br. Med. Bull. 73–74 (01), 1–15.
Malla, A.K., Norman, R.M., Manchanda, R., McLean, T.S., Harricharan, R., Cortese, L.,
Townsend, L.A., Scholten, D.J., 2002. Status of patients with ﬁrst-episode psychosis
after one year of phase-speciﬁc community-oriented treatment. Psychiatr. Serv. 53
(4), 458–463.
McGlashan, T.H., 1988. A selective review of recent North American long-term followup
studies of schizophrenia. Schizophr. Bull. 14 (4), 515–542.
Miyake, A., Friedman, N.P., Emerson, M.J., Witzki, A.H., Howerter, A., 2000. The unity
and diversity of executive functions and their contributions to complex “frontal
lobe” tasks: a latent variable analysis. Cogn. Psychol. 41, 49–100.
Morris, N., Jones, D.M., 1990. Memory updating in working memory: the role of the
central executive. Br. J. Psychol. 81, 111–121.
Oliveira, R., 2002. Teste não verbal de inteligência. Vetor Editora Psico-Pedagógica, São
Paulo.
Palmer, B.W., Dawes, S.E., Heaton, R.K., 2009. What do we know about neuropsycho-
logical aspects of schizophrenia? Neuropsychol. Rev. 19 (3), 365–384.
Raffard, S., Bayard, S., 2012. Understanting the executive functioning heterogeneity in
schizophrenia. Brain Cogn. 79 (1), 60–69.
Rapoport, J.L., Addington, A.M., Frangou, S., Psych, M.R.C., 2005. The neurodevelop-
mental model of schizophrenia. Mol. Psychiatry 10, 434–449.Rogers, R.D., Monsell, S., 1995. Costs of a predictable switch between simple cognitive
tasks. J. Exp. Psychol. Gen. 124, 207–231.
Rund, B.R., Melle, I., Frils, S., Johannessen, J.O., Larsen, T.K., Midboe, L.J., Opjordsmoen, S.,
Simonsen, E., Vaglum, P., McGlashan, T., 2007. The course of neurocognitive
functioning in ﬁrst-episode psychosis and its relation to premorbid adjustment,
duration of untreated psychosis, and relapse. Schizophr. Res. 91 (1-3), 132–140.
Spiker, H.T., Townsend, B., Unterman, D., Voisinet, S., Welp, R., 1987. Sustained
remission in drug-free schizophrenic patients. Am. J. Psychiatry 144, 1306–1309.
Tandon, R., Targum, S.D., Nasrallah, H.A., Ross, R., 2006. Strategies for maximizing clinical
effectiveness in the treatment of schizophrenia. J. Psychiatr. Pract. 12 (6), 348–363.
Tandon, R., Keshavan, M.S., Nasrallah, H.A., 2008. Schizophrenia, “just the facts” what
we know in 2008. 2. Epidemiology and etiology. Schizophr. Res. 102 (1–3), 1–18.
Teuber, H.L., 1972. Unity and diversity of frontal lobe functions. Acta Neurobiol. Exp.
(Wars.) 32 (2), 615–656.
Torgalsboen, A.K., Mohn, C., Rund, B., 2014. Neurocognitive predictors of remission of
symptoms and social and role functioning in the early course of ﬁrst-episode
schizophrenia. Psychiatry Res. 216 (1), 1–5.
Weickert, T.W., Goldberg, T.E., Gold, J.M., Bigelow, L.B., Egan, M.F., Daniel, R.,
Weinberger, D.R., 2000. Cognitive impairments in patients with schizophrenia
displaying preserved and compromised intellect. Arch. Gen. Psychiatry 57 (9),
907–913.
Wilson, B.A., Alderman, N., Burgess, P.W., Emslie, H., Evans, J.J., 2003. Behavioural
Assessment of Dysexecutive Syndrome (BADS). JOPED 5 (2), 33–37.
Wood, S.J., Allen, N.B., Pantelis, C., 2009. The Neuropsychology of Mental Illness.
Cambridge University Press, New York.
Yntema, D.B., 1963. Keeping track of several things at once. Hum. Factors 5, 7–17.
